Conference Day 2

10:20 am - 10:30 am Chairman's Welcome and Summary of Day 1

10:30 am - 11:15 am Transitioning Towards a Decentralised Manufacturing Strategy

Ohad Karnieli - CEO, ADVA Biotechnology
  • Discuss how - and why - ADVA ave proactively moved from a centralised to decentralised manufacturing strategy
  • Examine how decentralised manufacturing can alleviate the challenges posed by closing borders and ongoing flight cancellations
  • Weigh up the costs of goods with the benefits of transitioning towards decentralisation with reference to logistics management, regulatory approval and speed of supply
  • Identify critical elements to enable decentralized manufacturing

Ohad Karnieli

ADVA Biotechnology

11:15 am - 12:00 pm Session Reserved For Sponsor

12:00 pm - 12:45 pm Looking at the Research Perspective: Translation under Covid-19 at UCL

Pamela Tranter - Head of Translational Research Group, UCL
  • Outline the biggest challenges presented to UCL's translational model when identifying high potential candidates
  • Discuss the role of academic research and translation in addressing the current pandemic environment, and the challenges inherent with timeline management
  • Analyse how changes in industry priorities and broader governmental support an be used to maximise the relationship between the academic and private sectors to fast-track viable therapies into development


Pamela Tranter

Head of Translational Research Group

12:45 pm - 2:00 pm Lunch Break

2:00 pm - 2:45 pm Maintaining a C&GT Biotech through the COVID-19 Crisis: Challenges and Opportunities

Miguel Forte - CEO, Bone Therapeutics
  • Engage with the bone Therapeutics perspective on the changes to clinical development for allogenic cell therapies under Covid-19
  • Discuss strategies to re-enforce your clinical operations to mitigate against delays and maintain development consistency

Miguel Forte

Bone Therapeutics

2:45 pm - 3:30 pm Session Reserved for Sponsor

3:30 pm - 4:15 pm Case Study: Stem Cell Raw Materials Qualification at Novo Nordisk

Pernille Linnert Jensen - Senior Scientist - Project Lead Stem Cell R&D, Novo Nordisk
  • How to balance safety, compliance and speed when qualifying raw materials for very different stem cell therapy purposes like cell banking or drug product manufacture for Clinical Phase I/II, Phase III or the Market?

Pernille Linnert Jensen

Senior Scientist - Project Lead Stem Cell R&D
Novo Nordisk

4:15 pm - 4:20 pm Chairman's Summary and End of Webinar